Precision medicine, genetic profiling, targeted therapies
A three-stage customized journey to fight cancer
Every cancer is unique: understanding its deep nature is key to effectively fight it. Virtually all the tumors arise because of specific genomic alterations, driving cancer growth and making it different from any other. The tumor’s genetic profiling can identify the alterations in the cancer DNA, both in liquid and solid tumors.
Every cancer is unique: a targeted strategy is the best way to effectively fight it. By exploiting its highly qualified Scientific Committee, which integrates the genetic results with the clinical experience in targeted therapies, Medendi can find the right therapeutic options for every specific cancer type, and propose patients the best treatment solutions.
By examining the patient’s clinical documentation, the Medendi Scientific Committee evaluates the opportunity to proceed with the genomic profiling of the tumor.
Medendi arranges the genomic profiling test of the patient’s tumor, advising the most appropriate molecular test and managing the whole process with no stress for the patient.
Building on the Member’s clinical experience, the Scientific Committee analyzes the genetic test results to indicate the most appropriate therapeutic options available, including clinical trials.
A patient story:
Andrea’s tumor genomic profiling test has revealed a specific mutation, known to cause resistance to the therapy he was undergoing. These results allowed Andrea to shift immediately to a different treatment, known to be effective in this setting. This turned out the be the case.
Thanks to the consistent reduction in tumor volume, Andrea had a successful liver surgery in November 2020 and today he is disease-free (under maintenance therapy).
The patient is not required to move, and the full recommendation process takes on average 4 weeks.
The Evaluation process starts online by filling the contact form or scheduling a call with a Medendi Specialist; the clinical documentation is sent by email and Medendi replies in approximately three days.
The genetic profiling test is made on the same tissue sample used for diagnosis (the patient may obtain the sample from the treating anatomo-histopathology department) or using a few ml of a peripheral blood withdraw.
The Medendi Scientific Committee interprets the results of the genetic profiling and shares with the patient its recommendation for the most appropriate treatment options available. The genetic profiling + recommendation phase is completed in about 3 weeks.
The Medendi Scientific Committee includes highly competent experts, members of trusted Italian and foreign research centers for oncology. Prof. Maurizio Scaltriti, Medendi Vice President, formerly Associate Director of Translational Science, Center for Molecular-Based Therapies – Memorial Sloan Kettering Cancer Center in New York, currently Vice President of Translational Medicine, Early Oncology – AstraZeneca, is coordinating the Scientific Committee and the assignment of the medical cases to the specialist members.
Executive Chairman, Operations
Scientific Advisor, VP
Associate Director of
Translational Science, Center
for Molecular-Based Therapies ›
Memorial Sloan Kettering
Finance and Legal
Branding, Graphic Design